# Cancer‐associated fibroblasts are associated with CD8+ T cell depletion and poor prognosis in colorectal adenocarcinoma: a multi‐omics and machine learning analysis

**Authors:** Myungsun Shim, One‐Zoong Kim, Byoung Kwan Son, Jung Ki Jo, Seung Wook Lee, Hong Sang Moon, Hyung Suk Kim, Mi Jung Kwon, Sung Hak Lee, Yung‐Kyun Noh, Kyueng‐Whan Min

PMC · DOI: 10.1002/2056-4538.70076 · The Journal of Pathology: Clinical Research · 2026-02-22

## TL;DR

This study shows that cancer-associated fibroblasts are linked to reduced T cell presence and worse outcomes in colorectal cancer patients.

## Contribution

The study introduces a machine learning model that improves survival prediction by incorporating aCAF features and multi-omics data.

## Key findings

- aCAFs correlate with advanced tumor stage and reduced CD8+ and CD4+ T cell infiltration.
- aCAF-related genes are involved in immunosuppressive and tumor progression pathways.
- Machine learning models using aCAFs show better prognostic accuracy for survival outcomes.

## Abstract

Fibroblastic proliferation in various tumor microenvironments influences cancer survival through complex interactions with diverse immune responses. This study investigated the impact of histologically unique activated cancer‐associated fibroblasts (aCAFs) on survival outcomes and immune responses and examined their association with various pathophysiological mechanisms. We analyzed a total of 1,024 colorectal adenocarcinoma patients from two cohorts. aCAFs were evaluated based on hematoxylin and eosin‐stained whole‐slide images, and their associations with clinicopathological features, immune cell infiltration, and survival were assessed. We developed a machine learning‐based survival prediction model incorporating aCAFs and clinicopathologic parameters. Additionally, we performed differential gene expression analysis, functional enrichment analyses, and in vitro drug screening of aCAF‐related genes. aCAFs were associated with advanced T stage, lymphovascular invasion, perineural invasion, and decreased CD8+ and CD4+ T cell infiltration. aCAFs were also associated with worse overall and disease‐free survival in both univariate and multivariate analyses. Functional enrichment analysis revealed that aCAF‐related genes were implicated in immunosuppressive signaling, oxidative stress regulation, and tumor progression pathways. Survival prediction models based on machine learning and incorporating aCAFs demonstrated superior prognostic accuracy for overall survival and disease‐free survival compared to models excluding aCAFs. Our analysis of aCAFs' association with immune responses through bioinformatics‐based genomic analysis and machine learning provides a foundation for future research in CRC patients.

## Linked entities

- **Diseases:** colorectal adenocarcinoma (MONDO:0005008)

## Full-text entities

- **Genes:** PCAT1 (prostate cancer associated transcript 1) [NCBI Gene 100750225] {aka PCA1, PCAT-1, PiHL}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, SAA3P (serum amyloid A3, pseudogene) [NCBI Gene 6290] {aka SAA3}, POSTN (periostin) [NCBI Gene 10631] {aka OSF-2, OSF2, PDLPOSTN, PN}, PDGFRA (platelet derived growth factor receptor alpha) [NCBI Gene 5156] {aka CD140A, PDGFR-2, PDGFR2}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, CIITA (class II major histocompatibility complex transactivator) [NCBI Gene 4261] {aka C2TA, CIITAIV, MHC2D1, MHC2TA, NLRA}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}, MMP11 (matrix metallopeptidase 11) [NCBI Gene 4320] {aka SL-3, ST3, STMY3}, CXCL2 (C-X-C motif chemokine ligand 2) [NCBI Gene 2920] {aka CINC-2a, GRO2, GROb, MGSA-b, MIP-2a, MIP2}, mucin [NCBI Gene 100508689], CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, MRC2 (mannose receptor C-type 2) [NCBI Gene 9902] {aka CD280, CLEC13E, ENDO180, UPARAP}, ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58] {aka ACTA, ASMA, CFTD, CFTD1, CFTDM, CMYO2A}, TPM2 (tropomyosin 2) [NCBI Gene 7169] {aka AMCD1, CMYO23, CMYP23, DA1, DA2B, DA2B4}, SLPI (secretory leukocyte peptidase inhibitor) [NCBI Gene 6590] {aka ALK1, ALP, BLPI, HUSI, HUSI-1, HUSI-I}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, HOPX (HOP homeobox) [NCBI Gene 84525] {aka CAMEO, HOD, HOP, LAGY, NECC1, OB1}, CFD (complement factor D) [NCBI Gene 1675] {aka ADIPSIN, ADN, DF, PFD}, MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312] {aka CLG}, LRG1 (leucine rich alpha-2-glycoprotein 1) [NCBI Gene 116844] {aka HMFT1766, LRG}, LMNA (lamin A/C) [NCBI Gene 4000] {aka CDCD1, CDDC, CMD1A, CMT2B1, EMD2, FPL}, HLA-DRB1 (major histocompatibility complex, class II, DR beta 1) [NCBI Gene 3123] {aka DRB1, HLA-DR1B, HLA-DRB, SS1}, ACTA2 (actin alpha 2, smooth muscle) [NCBI Gene 59] {aka ACTSA, SMDYS}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, FAP (fibroblast activation protein alpha) [NCBI Gene 2191] {aka DPPIV, FAPA, FAPalpha, SIMP}, CD74 (CD74 molecule) [NCBI Gene 972] {aka CLIP, DHLAG, HLADG, II, Ia-GAMMA, p33}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, PDGFRB (platelet derived growth factor receptor beta) [NCBI Gene 5159] {aka CD140B, IBGC4, IMF1, JTK12, KOGS, OPDKD}, AGTR1 (angiotensin II receptor type 1) [NCBI Gene 185] {aka AG2S, AGTR1B, AT1, AT1AR, AT1B, AT1BR}, TAGLN (transgelin) [NCBI Gene 6876] {aka SM22, SM22-alpha, SMCC, TAGLN1, TGLN, WS3-10}, GABARAP (GABA type A receptor-associated protein) [NCBI Gene 11337] {aka ATG8A, GABARAP-a, MM46}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, DPT (dermatopontin) [NCBI Gene 1805] {aka TRAMP}, VIM (vimentin) [NCBI Gene 7431], TPM1 (tropomyosin 1) [NCBI Gene 7168] {aka C15orf13, CMD1Y, CMH3, HEL-S-265, HTM-alpha, LVNC9}, TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076] {aka CLGI, EPA, EPO, HCI, TIMP, TIMP-1}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, HLA-DRA (major histocompatibility complex, class II, DR alpha) [NCBI Gene 3122] {aka HLA-DRA1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, HAS1 (hyaluronan synthase 1) [NCBI Gene 3036] {aka HAS}, CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}, ITIH2 (inter-alpha-trypsin inhibitor heavy chain 2) [NCBI Gene 3698] {aka H2P, ITI-HC2, SHAP}
- **Diseases:** PNI (MESH:D052958), CRC (MESH:D003110), breast cancer (MESH:D001943), carcinogenesis (MESH:D063646), aCAF (MESH:D009369), Tumor Immune Dysfunction and (MESH:D007154), GBM (MESH:D000141), Neutrophilic abscess (MESH:D000038), inflammatory (MESH:D007249), OXIDATIVE DAMAGE RESPONSE (MESH:D004194), metastasis (MESH:D009362), SMALL CELL LUNG CANCER (MESH:D018288), death (MESH:D003643), small cell lung cancer (MESH:D055752), SASP (MESH:D008579), CRC (MESH:D015179)
- **Chemicals:** ascorbate (MESH:D001205), aldarate (-), H&amp;E (MESH:D006371)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12928035/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12928035/full.md

## References

48 references — full list in the complete paper: https://tomesphere.com/paper/PMC12928035/full.md

---
Source: https://tomesphere.com/paper/PMC12928035